Chemical phylogenetics of histone deacetylases

Cited by (769)

Items 301–400 of 769

1. Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition
   Dahea You, Jason R. Richardson, Lauren M. Aleksunes · 2020 · Drug Metabolism and Disposition
2. Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma
   Sanne Venneker, Alwine B. Kruisselbrink, Zuzanna Baranski, Ieva Palubeckaitė, Inge H. Briaire‐de Bruijn, Jan Oosting, Pim J. French, Erik H.J. Danen, Judith V.M.G. Bovée · 2020 · Cancers
3. Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor
   Anna Skwarska, Ewen D. D. Calder, Deborah Sneddon, Hannah R. Bolland, Maria L. Odyniec, Ishna N. Mistry, Jennifer Martin, Lisa K. Folkes, Stuart J. Conway, Ester M. Hammond · 2021 · Cell chemical biology
4. Translating HDAC inhibitors in Friedreich’s ataxia
   Elisabetta Soragni, Joel M. Gottesfeld · 2016 · Expert Opinion on Orphan Drugs
5. Effect of Fusarium-Derived Metabolites on the Barrier Integrity of Differentiated Intestinal Porcine Epithelial Cells (IPEC-J2)
   Alexandra Springler, Galina-Jacqueline Vrubel, Elisabeth Mayer, Gerd Schatzmayr, Barbara Novak · 2016 · Toxins
6. Macrocyclic Peptoid–Peptide Hybrids as Inhibitors of Class I Histone Deacetylases
   Christian Adam Olsen, Ana Montero, Luke J. Leman, M. Reza Ghadiri · 2012 · ACS Medicinal Chemistry Letters
7. Histone 4 lysine 5/12 acetylation enables developmental plasticity of Pristionchus mouth form
   Michael S. Werner, Tobias Loschko, Thomas King, Shelley Reich, Tobias Theska, Mirita Franz‐Wachtel, Boris Maček, Ralf J. Sommer · 2023 · Nature Communications
8. Mechanisms of HDACs in cancer development
   Ying Zhang, Haotian Wang, Zhumei Zhan, Lin Gan, Ou Bai · 2025 · Frontiers in Immunology
9. Epigenetics of Alzheimer's Disease and Frontotemporal Dementia
   Chendhore S. Veerappan, Sama F. Sleiman, Giovanni Coppola · 2013 · Neurotherapeutics
10. Panobinostat for the treatment of multiple myeloma
    Paola E. Neri, Nizar Jacques Bahlis, Sagar Lonial · 2012 · Expert Opinion on Investigational Drugs
11. Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids
    Rodrigo Mendoza‐Sanchez, David Cotnoir‐White, Justyna Kulpa, Isabel Jutras, Joshua Pottel, Nicolas Moitessier, Sylvie Mader, James L. Gleason · 2015 · Bioorganic & Medicinal Chemistry
12. HDAC4 is required for inflammation-associated thermal hypersensitivity
    Megan Crow, Nikita Khovanov, Jayne H. Kelleher, Simone Sharma, Andrew D. Grant, Yury D. Bogdanov, John N. Wood, Stephen Brendan McMahon, Franziska Denk · 2015 · The FASEB Journal
13. Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Bearing a Pyrazole Scaffold and a Cinnamoyl Linker
    Chiara Zagni, Andrea Citarella, Mahjoub Oussama, Antonio Rescifina, Alessandro Maugeri, Michele Navarra, Angela Scala, Anna Piperno, Nicola Micale · 2019 · International Journal of Molecular Sciences
14. Class I Histone Deacetylase Inhibition by Tianeptinaline Modulates Neuroplasticity and Enhances Memory
    Zhao, Wen-Ning, Ghosh, Balaram, Tyler, Marshall, Lalonde, Jasmin, Joseph, Nadine F., Kosaric, Nina, Fass, Daniel M., Tsai, Li-Huei, Mazitschek, Ralph, Haggarty, Stephen J. · 2018 · ACS Chemical Neuroscience
15. Chemical editing of macrocyclic natural products and kinetic profiling reveal slow, tight-binding histone deacetylase inhibitors with picomolar affinities
    Kitir, Betül, Maolanon, Alex R., Ohm, Ragnhild G., Colaço, Ana R., Fristrup, Peter, Madsen, Andreas S., Olsen, Christian A. · 2017 · Biochemistry
16. Lactate-dependent transcriptional regulation controls mammalian eye morphogenesis
    Nozomu Takata, Jason M. Miska, Marc A. Morgan, Priyam A. Patel, Leah K. Billingham, Neha Joshi, Matthew John Schipma, Zachary J. Dumar, Nikita Joshi, Alexander V. Misharin et al. · 2023 · Nature Communications
17. Is an epigenetic switch the key to persistent extinction?
    James M. Stafford, K. Matthew Lattal · 2011 · Neurobiology of Learning and Memory
18. How the flexibility of human histone deacetylases influences ligand binding: an overview
    Nathalie Deschamps, Claudia Avello Simões‐Pires, Pierre‐Alain Carrupt, Alessandra Nurisso · 2015 · Drug Discovery Today
19. Chiral Mercaptoacetamides Display Enantioselective Inhibition of Histone Deacetylase 6 and Exhibit Neuroprotection in Cortical Neuron Models of Oxidative Stress
    Jay H. Kalin, Hankun Zhang, Sophie Gaudrel‐Grosay, Giulio Vistoli, Alan P. Kozikowski · 2012 · ChemMedChem
20. HDAC6 Modulates Signaling Pathways Relevant to Synaptic Biology and Neuronal Differentiation in Human Stem Cell-Derived Neurons
    Jonathan Iaconelli, Lucius L. Xuan, Rakesh Karmacharya · 2019 · International Journal of Molecular Sciences
21. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma
    Ekaterina Pak, Ethan L. MacKenzie, Xuesong Zhao, Maria F. Pazyra‐Murphy, Paul M.C. Park, Lei Wu, Daniel L Shaw, Emily Addleson, Suzanne Cayer, Begoña G-C Lopez et al. · 2019 · Neuro-Oncology
22. The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo
    Salomé Paillas, Chee Kin Then, Susan Kilgas, Jia-Ling Ruan, James M Thompson, Amy Elliott, Sean Smart, Anne E. Kiltie · 2020 · International Journal of Radiation Oncology*Biology*Physics
23. CaMKII exacerbates heart failure progression by activating class I HDACs
    Manling Zhang, Xue Yang, Raymond J. Zimmerman, Qin Wang, Mark A. Ross, Jonathan M. Granger, Elizabeth D. Luczak, Djahida Bedja, Hong Jiang, Ning Feng · 2020 · Journal of Molecular and Cellular Cardiology
24. Hydroxamic acid-modified peptide microarrays for profiling isozyme-selective interactions and inhibition of histone deacetylases
    Carlos Moreno–Yruela, Michael Bæk, Adela-Eugenie Vrsanova, Clemens Schulte, Hans Michael Maric, Christian Adam Olsen · 2021 · Nature Communications
25. Synergistic induction of miR-126 by hypoxia and HDAC inhibitors in cardiac myocytes
    Huaping Shi, Lei Chen, Huilan Wang, Shoukang Zhu, Chunming Dong, Keith A. Webster, Jianqin Wei · 2012 · Biochemical and Biophysical Research Communications
26. Epigenetic alterations in osteosarcoma: promising targets
    Binghao Li, Zhaoming Ye · 2014 · Molecular Biology Reports
27. Romidepsin for the treatment of T-cell lymphomas
    Angie McGraw · 2013 · American Journal of Health-System Pharmacy
28. Next generation histone deacetylase inhibitors: the answer to the search for optimized epigenetic therapies?
    Florian Thaler, Saverio Minucci · 2011 · Expert Opinion on Drug Discovery
29. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy
    Madeleine A. Duvic, Susan Elaine Bates, Richard Piekarz, Robin A. Eisch, Youn H. Kim, Adam Lerner, Tadeusz Robak, Alexey V. Samtsov, Jürgen Christian Becker, William F. McCulloch et al. · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
30. The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines
    Fiona R. Kolbinger, Emily Koeneke, Johannes Ridinger, Tino Heimburg, Michael Müller, Theresa Bayer, Wolfgang Sippl, Manfred Jung, Nikolas Gunkel, Aubry K. Miller et al. · 2018 · Archives of Toxicology
31. Design and Optimization of Novel Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-Substituted Aromatic Amides Bearing Potent Activities against Tumor Growth and Metastasis
    Feifei Yang, Tao Zhang, Haigang Wu, Yang Yang, Ning Liu, Ang Chen, Qiang Li, Jingjie Li, Liwen Qin, Beier Jiang et al. · 2014 · Journal of Medicinal Chemistry
32. Total Synthesis of (18S)‐ and (18R)‐Homolargazole by Rhodium‐Catalyzed Hydrocarboxylation
    Christoph Schotes, Dmytro Ostrovskyi, Johanna Senger, Karin Schmidtkunz, Manfred Jung, Bernhard Breit · 2014 · Chemistry - A European Journal
33. Kinetically Selective Inhibitors of Human Carbonic Anhydrase Isozymes I, II, VII, IX, XII, and XIII
    V. Talibov, Vaida Linkuvienė, Daumantas Matulis, U. Helena Danielson · 2016 · Journal of Medicinal Chemistry
34. Emerging Roles for Histone Deacetylases in Pulmonary Hypertension and Right Ventricular Remodeling (2013 Grover Conference series)
    Maria A. Cavasin, Kurt R. Stenmark, Timothy A. McKinsey · 2015 · Pulmonary Circulation
35. Mc1568 Inhibits Hdac6/8 Activity and Influenza a Virus Replication in Lung Epithelial Cells: Role of Hsp90 Acetylation
    Simona Panella, Maria Elena Marcocci, Ignacio Celestino, Sérgio Valente, Clemens Zwergel, Domenica Donatella Li Puma, Lucia Nencioni, Antonello Mai, Anna Teresa Palamara, Giovanna Simonetti · 2016 · Future Medicinal Chemistry
36. Histone deacetylase inhibitors in the treatment for multiple myeloma
    Teru Hideshima, Kenneth Carl Anderson · 2013 · International Journal of Hematology
37. Diversity-Oriented Synthetic Strategies Applied to Cancer Chemical Biology and Drug Discovery
    Ian Collins, Alan M. Jones · 2014 · Molecules
38. Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile
    Žarko Bošković, Melissa M. Kemp, Allyson M. Freedy, Vasanthi S. Viswanathan, Marius S. Pop, Jason H. Fuller, Nicole M. Martínez, Samuel Figueroa-Lazú, Jiyoung A. Hong, Timothy A. Lewis et al. · 2016 · ACS Chemical Biology
39. Validation of histone deacetylase 3 as a therapeutic target in castration‐resistant prostate cancer
    Anette McLeod, James P. Stice, S. Wardell, Holly M. Alley, Ching-Yi Chang, D. McDonnell · 2018 · The Prostate
40. Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma
    Marcelo Lima Ribeiro, Diana Reyes-Garau, Marc Armengol, Miranda Fernández-Serrano, Gaël Roué · 2019 · Frontiers in Genetics
41. Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase‑dependent manner
    Xianggui Yuan, Yurong Huang, Teng Yu, Huawei Jiang, Yang Xu, Xiaoying Zhao · 2019 · Oncology Letters
42. A novel HDAC1/2 inhibitor suppresses colorectal cancer through apoptosis induction and cell cycle regulation
    Hsueh‐Yun Lee, Di-Wei Tang, Chi-Yuan Liu, Er-Chieh Cho · 2021 · Chemico-Biological Interactions
43. Resolving the deceptive isoform and complex selectivity of HDAC1/2 inhibitors
    N. Connor Payne, Ralph Mazitschek · 2022 · Cell chemical biology
44. Pan-histone deacetylase inhibitors regulate signaling pathways involved in proliferative and pro-inflammatory mechanisms in H9c2 cells
    Gipsy Majumdar, Piyatilake Adris, Neha Bhargava, Hao Chen, Rajendra Raghow · 2012 · BMC Genomics
45. Methylarginine targeting chimeras for lysosomal degradation of intracellular proteins
    Laurence J. Seabrook, Carolina N. Franco, Cody A. Loy, Jaida M. Osman, Callie Fredlender, Jan Zimak, Melissa Campos, Steven T. Nguyen, Richard L. Watson, Samantha R. Levine et al. · 2024 · Nature Chemical Biology
46. Natural Products as Zinc‐Dependent Histone Deacetylase Inhibitors
    Shuai Tan, Zhaopeng Liu · 2015 · ChemMedChem
47. Targeting Histone Deacetylases: Development of Vorinostat for the Treatment of Cancer
    Victoria M. Richon · 2010 · Epigenomics
48. Early prediction of response to Vorinostat in an orthotopic rat glioma model
    Wei Li, Samuel Hong, Younghyoun Yoon, Scott N. Hwang, Jaekeun C. Park, Zhaobin Zhang, Jeffrey J. Olson, Xiaoping Philip Hu, Hyunsuk Shim · 2012 · NMR in Biomedicine
49. Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells
    Liang Shan, Sifei Xing, Hung‐Chih Yang, Hao Zhang, Joseph B. Margolick, Robert F. Siliciano · 2013 · Journal of Antimicrobial Chemotherapy
50. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting
    Sunil Arani Reddy · 2016 · Critical Reviews in Oncology/Hematology
51. Histone deacetylase III as a potential therapeutic target for the treatment of lethal sepsis
    Ting Zhao, Yongqing Li, Baoling Liu, Roderick Terry Bronson, Ihab F. Halaweish, Hasan Badre Alam · 2014 · The Journal of Trauma: Injury, Infection, and Critical Care
52. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
    Francine M. Foss, Bertrand Coiffier, Steven Michael Horwitz, Barbara Pro, Henry Miles Prince, Lubomir Sokol, Matthew J. Greenwood, Adam Lerner, Dolores M. Caballero, Eugeniusz Baran et al. · 2014 · Biomarker Research
53. Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells
    Katrin Noack, Nisintha Mahendrarajah, Dorle Hennig, Luisa Schmidt, Florian Grebien, Dagmar Hildebrand, Markus Christmann, Bernd Kaina, Andreas Sellmer, Siavosh Mahboobi et al. · 2016 · Archives of Toxicology
54. A Fluorescence‐Lifetime‐Based Binding Assay for Class IIa Histone Deacetylases
    Christian Meyners, Monique Mertens, Pablo Wessig, Franz‐Josef Meyer‐Almes · 2016 · Chemistry - A European Journal
55. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment
    Jing Shen, Sara Najafi, Sina Stäble, Johannes Fabian, Emily Koeneke, Fiona R. Kolbinger, Jagoda K. Wrobel, Benjamin Meder, Martin Distel, Tino Heimburg et al. · 2018 · Cell Death and Differentiation
56. Distinct biochemical properties of the class I histone deacetylase complexes
    Kwangwoon Lee, Samuel D. Whedon, Zhipeng A. Wang, Philip A. Cole · 2022 · Current Opinion in Chemical Biology
57. Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures
    Avisek Majumder · 2023 · Cancers
58. Targeting of histone deacetylases in brain tumors
    Jonas Ecker, Olaf Witt, Till Milde · 2013 · CNS Oncology
59. A potent trifluoromethyl ketone histone deacetylase inhibitor exhibits class-dependent mechanism of action
    Andreas S. Madsen, Christian Adam Olsen · 2015 · MedChemComm
60. Roles of HDAC2 and HDAC8 in Cardiac Remodeling in Renovascular Hypertensive Rats and the Effects of Valproic Acid Sodium
    Ruifang Li, Shanshan Cao, Weijin Fang, Ying Song, Xueting Luo, Hongyun Wang, Jiangang Wang · 2016 · Pharmacology
61. Inhibiting stromal Class I HDACs curbs pancreatic cancer progression
    Gaoyang Liang, Tae Gyu Oh, Nasun Hah, Hervé Tiriac, Yu Shi, Morgan Truitt, Corina E. Antal, Annette R. Atkins, Yuwenbin Li, Cory Richard Fraser et al. · 2023 · Nature Communications
62. PROTAC‐Mediated HDAC7 Protein Degradation Unveils Its Deacetylase‐Independent Proinflammatory Function in Macrophages
    Kailibinuer Kadier, Tian Niu, Baoli Ding, Boya Chen, Xuxin Qi, Danni Chen, Xirui Cheng, Yi-zheng Fang, Jiahao Zhou, Wenyi Zhao et al. · 2024 · Advanced Science
63. Changes in cardiac Nav1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors
    Qin Xu, Dakshesh Patel, Xian Zhang, Richard D. Veenstra · 2016 · American Journal of Physiology-Heart and Circulatory Physiology
64. Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts
    Katherine B. Schuetze, Matthew S. Stratton, Weston W. Blakeslee, Michael F. Wempe, Florence F. Wagner, Edward B. Holson, Yin‐Ming Kuo, Andrew J. Andrews, Tonya M. Gilbert, Jacob M. Hooker et al. · 2017 · Journal of Pharmacology and Experimental Therapeutics
65. HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice
    Farhana Sakloth, Lefteris Manouras, Kleopatra Avrampou, Vasiliki Mitsi, Randal A. Serafini, Kerri D. Pryce, Valeria Cogliani, Olivier Berton, Matthew B. Jarpe, Venetia Zachariou · 2020 · Psychopharmacology
66. Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening
    Donya Naz Divsalar, Conrad Veranso Simoben, Cole Schonhofer, Khumoekae Richard, Wolfgang Sippl, Fidele Ntie‐Kang, Ian Tietjen · 2020 · Frontiers in Pharmacology
67. Histone Modifications and Chondrocyte Fate: Regulation and Therapeutic Implications
    Chao Wan, Fengjie Zhang, Hanyu Yao, Haitao Li, Rocky S. Tuan · 2021 · Frontiers in Cell and Developmental Biology
68. Synthesis, antitumor, and apoptosis-inducing activities of novel 5-arylidenethiazolidine-2,4-dione derivatives: Histone deacetylases inhibitory activity and molecular docking study
    Abdelrahman Hamdi, Walaa M. El-Husseiny, Dina I. A. Othman, Abdullah Haikal, Ahmed H.H. Bakheit, Adel S. El‐Azab, Mohamed Hamed Al-Agamy, Alaa A.‐M. Abdel‐Aziz · 2022 · European Journal of Medicinal Chemistry
69. Trapoxin A Analogue as a Selective Nanomolar Inhibitor of HDAC11
    Thanh Tu Ho, Changmin Peng, Edward Seto, Hening Lin · 2023 · ACS Chemical Biology
70. Molecular Targets in the Treatment of Cardiac Hypertrophy
    Christian Kühn, Susanne S. Hille, Norbert Frey · 2015 · Springer eBooks
71. Pojamide: An HDAC3-Selective Ferrocene Analogue with Remarkably Enhanced Redox-Triggered Ferrocenium Activity in Cells
    Cory A. Ocasio, Supojjanee Sansook, Rhiannon N. Jones, Justin M. Roberts, Thomas G. Scott, Nikolaos Tsoureas, Peter Coxhead, Matthew Guille, Graham J. Tizzard, Simon John Coles et al. · 2017 · Organometallics
72. Connectivity mapping of a chronic kidney disease progression signature identified lysine deacetylases as novel therapeutic targets
    Vanessa R. Williams, Ana Konvalinka, Xuewen Song, Xiaohua Zhou, Rohan John, York Pei, James William Scholey · 2020 · Kidney International
73. Structural Biology of Human Metal-Dependent Histone Deacetylases
    Matthieu Schapira · 2011 · Handbook of experimental pharmacology
74. Mechanisms of transcription factor acetylation and consequences in hearts
    Devi Thiagarajan, Srinivasan Vedantham, Radha Ananthakrishnan, Ann Marie Schmidt, Ravichandran Ramasamy · 2016 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
75. Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy
    Suchi Raghunathan, Ramesh K. Goyal, Bhoomika M. Patel · 2016 · Canadian Journal of Physiology and Pharmacology
76. Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib
    Jennifer Effie Amengual, Sathyen Alwin Prabhu, Maximilian Lombardo, Kelly M. Zullo, Paul M. Johannet, Yulissa Gonzalez, Luigi Scotto, Xavier O. Jirau Serrano, Ying Wei, Jimmy Duong et al. · 2016 · Clinical Cancer Research
77. Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors.
    Seiya Hiranaka, Yuma Tega, K. Higuchi, Toshiki Kurosawa, Y. Deguchi, Mayumi Arata, A. Ito, M. Yoshida, Y. Nagaoka, T. Sumiyoshi · 2018 · ACS Medicinal Chemistry Letters
78. HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates
    Jeffrey Y. W. Mak, Kai‐Chen Wu, Praveer K. Gupta, Sheila Barbero, Maddison G. McLaughlin, Andrew J. Lucke, Jiahui Tng, Junxian Lim, Zhixuan Loh, Matthew J. Sweet et al. · 2021 · Journal of Medicinal Chemistry
79. Toward Isozyme-Selective Inhibitors of Histone Deacetylase As Therapeutic Agents for the Treatment of Cancer
    Sophia N. Ononye, Michael D. Van Heyst, Eric R. Falcone, Amy C. Anderson, Dennis L. Wright · 2012 · Pharmaceutical Patent Analyst
80. Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides That Restore Trafficking and Activity of ΔF508-CFTR
    Darren M. Hutt, Christian Adam Olsen, Chris J. Vickers, David Herman, Monica A. Chalfant, Ana Montero, Luke J. Leman, Renner Burkle, Bruce E. Maryanoff, William E. Balch et al. · 2011 · ACS Medicinal Chemistry Letters
81. Histone deacetylase1 promotes TGF-β1-mediated early chondrogenesis through down-regulating canonical Wnt signaling
    Xiaoju Huang, Jiajia Xu, Mingjian Huang, Jiao Li, Liming Dai, Kerong Dai, Xiaoling Zhang · 2014 · Biochemical and Biophysical Research Communications
82. Metabolic Regulation of the Epitranscriptome
    Justin M. Thomas, Pedro J. Batista, Jordan L. Meier · 2019 · ACS Chemical Biology
83. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice
    Ha‐Neui Kim, Jong-Ho Lee, Won Jong Jin, Sungjin Ko, Kyoungsuk Jung, Hyunil Ha, Zang Hee Lee · 2012 · European Journal of Pharmacology
84. Romidepsin
    Lily P H Yang · 2011 · Drugs
85. Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophy
    Matthew S. Stratton, Timothy A. McKinsey · 2014 · Biochemistry and Cell Biology
86. Kinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression
    Moreno-Yruela, Carlos, Fass, Daniel M., Cheng, Chialin, Herz, Joachim, Olsen, Christian A., Haggarty, Stephen J. · 2019 · ACS Chemical Neuroscience
87. ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy
    Seongjun Park, Sang Hoon Joo, Naeun Lee, Won‐Jun Jang, Ji Hae Seo, Chul‐Ho Jeong · 2021 · Archives of Pharmacal Research
88. Understanding Histone Deacetylases in the Cancer Development and Treatment: An Epigenetic Perspective of Cancer Chemotherapy
    Mudassier Ahmad, Abid Hamid, Aashiq Hussain, Rabiya Majeed, Yasrib Qurishi, Javeed Ahmad Bhat, Rauf Ahmad Najar, Asif Khurshid Qazi, Mohammad Afzal Zargar, Shashank Kumar Singh et al. · 2012 · DNA and Cell Biology
89. Histone deacetylase inhibition reduces cardiac connexin43 expression and gap junction communication
    Qin Xu, Xianming Lin, Laura E. Andrews, Dakshesh Patel, Paul D. Lampe, Richard D. Veenstra · 2013 · Frontiers in Pharmacology
90. Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Can Mediate Neuroprotection Independent of HDAC Inhibition
    Sama F. Sleiman, D. E. Olson, M. Bourassa, Saravanan S. Karuppagounder, Yan-Ling Zhang, J. Gale, F. Wagner, M. Basso, G. Coppola, J. Pinto et al. · 2014 · Journal of Neuroscience
91. Epigenetic Regulation of the Electrophysiological Phenotype of Human Embryonic Stem Cell-Derived Ventricular Cardiomyocytes: Insights for Driven Maturation and Hypertrophic Growth
    Maggie Zi Ying Chow, Lin Geng, Chi‐Wing Kong, Wendy Keung, Jacky Chun-kit Fung, Kenneth R. Boheler, Ronald A. Li · 2013 · Stem Cells and Development
92. Molecular Targets of Valeric Acid: A Bioactive Natural Product for Endocrine, Metabolic, and Immunological Disorders
    Bindu Kumari, Usha Kumari, Dhananjay Kumar Singh, Gulam Mohammed Husain, Dinesh Kumar Patel, Anshul Shakya, Ravi Bhushan Singh, Gyan Prakash Modi, Gireesh Kumar Singh · 2024 · Endocrine Metabolic & Immune Disorders - Drug Targets
93. Repeated vapor ethanol exposure induces transient histone modifications in the brain that are modified by genotype and brain region
    Andrey Finegersh, Carolyn Ferguson, Seth D. Maxwell, David Mazariegos, Daniel Farrell, Gregg E. Homanics · 2015 · Frontiers in Molecular Neuroscience
94. CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1
    Pei‐Ming Yang, Pei-Jie Lin, Ching‐Chow Chen · 2012 · Epigenetics
95. The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines
    Lukas M. Bollmann, Alexander Jan Skerhut, Yodita Asfaha, Nadine Horstick‐Muche, Helmut Hanenberg, Alexandra Hamacher, Thomas Kurz, Matthias Ulrich Kassack · 2022 · International Journal of Molecular Sciences
96. Class I HDAC inhibition stimulates cardiac protein SUMOylation through a post-translational mechanism
    Weston W. Blakeslee, Christina L. Wysoczynski, Kristofer S. Fritz, Jennifer K. Nyborg, Mair E. A. Churchill, Timothy A. McKinsey · 2014 · Cellular Signalling
97. Epigenomic regulation of heart failure: integrating histone marks, long noncoding RNAs, and chromatin architecture
    Timothy A. McKinsey, Thomas M. Vondriska, Yibin Wang · 2018 · F1000Research
98. Evidence for a non-canonical role of HDAC5 in regulation of the cardiac Ncx1 and Bnp genes
    Lillianne G. Harris, Sabina H. Wang, Santhosh Kumar Mani, Harinath Kasiganesan, C. James Chou, Donald R. Menick · 2015 · Nucleic Acids Research
99. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T‐cell lymphoma
    Francine M. Foss, Barbara Pro, Henry Miles Prince, Lubomir Sokol, Dolores M. Caballero, Steven Michael Horwitz, Bertrand Coiffier · 2016 · Cancer Medicine
100. Quantum polarized ligand docking investigation to understand the significance of protonation states in histone deacetylase inhibitors
     Subha Kalyaanamoorthy, Yi‐Ping Phoebe Chen · 2013 · Journal of Molecular Graphics and Modelling